Human CD300c / LMIR2 Protein
- Known as:
- Human CD300c / LMIR2 Protein
- Catalog number:
- CDC-H5224
- Product Quantity:
- 100ug
- Category:
- -
- Supplier:
- acrobyosystems
- Gene target:
- Human CD300c / LMIR2 Protein
Related genes to: Human CD300c / LMIR2 Protein
- Gene:
- CD300C NIH gene
- Name:
- CD300c molecule
- Previous symbol:
- -
- Synonyms:
- CMRF35, LIR, CMRF-35A, CMRF35A, IGSF16
- Chromosome:
- 17q25.1
- Locus Type:
- gene with protein product
- Date approved:
- 2005-02-08
- Date modifiied:
- 2016-10-05
Related products to: Human CD300c / LMIR2 Protein
Related articles to: Human CD300c / LMIR2 Protein
- This exploratory, hypothesis-generating study aimed to evaluate the potential genetically informed association between gene expression and lung adenocarcinoma (LUAD) risk, and to investigate the possible mediating role of CD62L⁻ monocytes using a multi-omics Mendelian randomization (MR) framework. - Source: PubMed
Publication date: 2026/01/24
Chen HuilingXue ZhichunHuang LiwenZeng YingTang MeiyanHan KunhuangChen JiaDeng XinyuFang Guiju - Myeloid-derived suppressor cells (MDSCs) are recognized as a key mediator of immunosuppression in aging, which induce immunosenescence and increase elderly people's susceptibility to infections, cancers, autoimmune diseases, and degenerative diseases. However, the commonly used MDSC markers overlap with those defining healthy and normal neutrophils or monocytes, which makes it challenging to distinguish MDSCs from their myeloid counterparts, and hampers deeper understanding of the pathophysiological functions of MDSCs. In this study, we compared MDSCs from aged mice to young controls using single-cell RNA sequencing. We established MDSC-specific gene signature, which revealed the general characteristics of MDSCs during aging, and thus facilitating distinguishing them from normal myeloid cells. Experimental study revealed that CD300c may serve as a specific marker for improved detection and enrichment of MDSCs in aging. CD11bGr1CD300c cells demonstrated a robust ability of T cell suppression. The universality and applicability of MDSC-specific gene signature have also been demonstrated in human myeloid cells. We also found that MDSCs from aged individuals shared the similar developmental trajectory with their myeloid counterparts, and may develop from mature myeloid cells, both in mice and human beings, which has been reported by a limited number of studies. Overall, our work extends the understanding of MDSCs in aging process. - Source: PubMed
Publication date: 2025/12/24
Su YaruWu RuiminAi HaochenZhong ZhaomingZou LinWang ZihanTu KewuTang LingzhengGao JiawenHuang YushengLiao CongruiZeng GuanhaiZhang HongyangJin JianZhu Siyuan - Despite advances in therapy, non-small cell lung cancer (NSCLC) continues to rank among the deadliest cancers worldwide. Targeting immunosuppressive components within the tumor microenvironment (TME) has emerged as a promising therapeutic strategy. Unlike M1 tumor-associated macrophages (TAMs), M2-like TAMs contribute to NSCLC progression by promoting an immunosuppressive tumor microenvironment (TME), highlighting the need for tumor microenvironment remodeling. CL7, a monoclonal antibody that targets the activating receptor CD300c on human monocytes and macrophages, was selected as a therapeutic candidate because CD300c engagement triggers MAPK and NF-κB signaling pathways, promoting M1 macrophage polarization and antitumor immune activation. To evaluate the therapeutic potential of CL7, we established an orthotopic NSCLC model by inoculating LLC-luc cells into the left lung of mice. We administered CL7 intraperitoneally at doses of 5 or 10 mg/kg twice a week. Only representative data from the 10 mg/kg CL7 group are shown to maintain consistency with subsequent analyses (flow cytometry, RT-qPCR, and IHC). Tumor growth was significantly suppressed in the CL7-treated group compared to the PBS control group. CL7 treatment also modulated the tumor microenvironment by increasing the population of M1 macrophages and CD8 T cells, while decreasing the population of regulatory T cells. Our findings suggest that CL7 exerts antitumor effects in NSCLC by reprogramming the immunosuppressive landscape of the TME and enhancing antitumor immunity. - Source: PubMed
Publication date: 2025/11/25
Kim SoyoungHan Ik-HwanLee SuinPark SujinJeon Jae-WonBae Hyunsu - Understanding the role of plasma proteins in the pathophysiology of epilepsy is crucial for uncovering novel biological mechanisms and therapeutic targets. Mendelian randomization (MR) provides a valuable tool for dissecting potentially causal associations between circulating proteins and disease risk. This study aimed to systematically assess potential causal relationships between the plasma proteome and epilepsy. - Source: PubMed
Publication date: 2025/10/30
Fu JingfengWu WeiShen Shangren - The CD300 family comprises immunoglobulin superfamily receptors that regulate immune cell function through inhibitory or activating signals. CD300A and CD300C form a paired receptor system that recognizes shared ligands but mediates opposing effects: CD300A transduces inhibitory signals, whereas CD300C promotes activation. - Source: PubMed
Publication date: 2025/09/05
Dias CarolinaLevi-Schaffer FrancescaEsteves Pedro José